Journal: The Journal of dermatological treatment

Article Title: An open-label prospective clinical study to assess the efficacy of increasing levocetirizine dose up-to four times in chronic spontaneous urticaria not controlled with standard dose.

PMID/MRN: 27779432

Publication Date: 2016-Oct-25

Abstract:

The EAACI/GA 2 LEN/EDF/WAO recommendation of increasing antihistamines' dose up-to 4-times in urticaria not adequately controlled with the standard dose is largely based on expert opinion. The objective of this study is to test the current urticaria guidelines of up-dosing antihistamines as second-line treatment. This was an open-label study conducted prospectively on 113 patients with chronic spontaneous urticaria. All patients were treated with sequentially increasing doses of levocetrizine (5mg, 10mg, 15mg and 20mg/day) every week till the patients became completely asymptomatic or dose of 20mg/day reached. Urticaria Activity Score (UAS)-7, urticaria-related quality-of-life (CU-Q2oL) and patients' global assessment were used to assess treatment response. Twenty-one (18.58%) patients became asymptomatic with levocetirizine 5mg/day, while fifty required higher doses of levocetirizine for complete control: 29/92 (31.52%), 6/63 (9.52%) and 15/57 (26.31%) with 10mg, 15mg and 20mg/day, respectively. The percentage of patients experiencing >75% improvement increased with increasing doses of levocetirizine: 26.54%, 53.98%, 60.17% and 69.91% with 5mg, 10mg, 15mg and 20mg/day respectively. Sequential up-dosing of levocetirizine produced a progressive improvement in both urticaria control (UAS-7) as well as quality-of-life (CU-Q2oL) without significantly increasing somnolence. Our results support the current recommendations of increasing antihistamines up-to 4-times the standard dose in patients who fail the first-line treatment. Clinical trial registry number (CTRI/2016/07/007099).